This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Schrödinger, Inc. | |
|---|---|
| Name | Schrödinger, Inc. |
| Type | Public |
| Founded | 1990 |
| Founder | Richard A. Friesner; Robert B. Baber |
| Headquarters | New York City, New York, United States |
| Key people | Ramy Farid; Richard A. Friesner; Robert B. Baber |
| Industry | Computational chemistry; Biotechnology; Pharmaceuticals |
| Products | Maestro; Jaguar; Glide; FEP+; LiveDesign |
| Revenue | (see Financial Performance and Corporate Governance) |
| Website | (omitted) |
Schrödinger, Inc. is an American company that develops computational platforms for drug discovery and materials design, combining physics-based modeling with machine learning and cheminformatics. The firm provides proprietary software and contract research services to academic institutions, biotechnology firms, and pharmaceutical companies, and it operates a drug discovery unit aimed at progressing internally discovered therapeutic candidates. Schrödinger has roots in academic research and maintains technical collaborations with leading laboratories and corporate partners.
Schrödinger emerged from academic initiatives in computational chemistry, founded by Richard A. Friesner and Robert B. Baber with antecedents in work at Columbia University, Princeton University, and Duke University. Early milestones included commercialization of electronic structure methods developed by teams associated with Harvard University, Massachusetts Institute of Technology, and Stanford University. The company expanded through the 1990s and 2000s in parallel with advances at IBM Research, Bell Labs, and Lawrence Berkeley National Laboratory in high-performance computing and algorithms. Strategic hires and investments connected Schrödinger to venture capital groups that backed biotechnology firms like Genentech and Amgen. A public offering linked the company to capital markets and placed it alongside public peers such as Exscientia, Atomwise, and Recursion Pharmaceuticals. Throughout its history, Schrödinger interacted with regulatory and translational institutions including U.S. Food and Drug Administration-related pathways and clinical networks affiliated with Johns Hopkins University and Mayo Clinic.
Schrödinger operates a mixed model combining software licensing, cloud services, and fee-for-service research collaborations. Customers in industry and academia—ranging from Pfizer and GlaxoSmithKline to University of California, San Francisco and University of Cambridge—license simulation tools for structure-based design and materials modeling. The company offers professional services similar to contract research organizations such as Charles River Laboratories and IQVIA, and it provides cloud compute through partnerships with providers like Amazon Web Services, Microsoft Azure, and Google Cloud Platform. Revenue streams include perpetual and subscription licenses, collaboration milestones with partners including Novartis and Bristol-Myers Squibb, and milestones linked to discovery programs with venture-backed biotech firms such as Moderna and Vertex Pharmaceuticals.
Schrödinger’s R&D integrates quantum chemistry, molecular mechanics, and statistical sampling methods rooted in theoretical work from Walter Kohn, John Pople, and Martin Karplus. The company advances force fields and free-energy perturbation approaches influenced by research groups at University of California, Berkeley, Columbia University, and University of Pittsburgh. Machine learning efforts draw on methods similar to those developed at Google DeepMind, OpenAI, and University of Oxford research teams. Schrödinger collaborates on method validation and benchmarking with consortia including Open Force Field, and engages with standards groups such as International Union of Pure and Applied Chemistry and computational initiatives at National Institutes of Health. The firm’s technical agenda spans lead optimization, ADMET prediction, and materials property prediction, intersecting with work produced by Lawrence Livermore National Laboratory and Argonne National Laboratory.
Flagship software offerings include graphical and workflow tools comparable in function to platforms used at Amgen and Eli Lilly, incorporating modules for quantum mechanics, docking, and free-energy calculations. Notable products provide integrated environments for medicinal chemists, structural biologists, and materials scientists to perform tasks analogous to those carried out in laboratories at Scripps Research and Cold Spring Harbor Laboratory. The product suite interoperates with third-party formats and databases such as Protein Data Bank, and it supports cheminformatics pipelines used by companies like Schering-Plough and Takeda. Schrödinger’s cloud and on-premises solutions compete with offerings from Simulations Plus and bespoke platforms developed at GlaxoSmithKline research sites.
The company maintains partnerships across academia, industry, and national laboratories. Strategic collaborations have involved corporations including AstraZeneca, Sanofi, and Eli Lilly and Company, and academic programs at Massachusetts Institute of Technology, Yale University, and University of Pennsylvania. Joint projects with biotechnology firms and contract research organizations have been announced with entities like CureVac and Catalent. Schrödinger participates in translational consortia linked to philanthropic organizations such as Bill & Melinda Gates Foundation and engages in collaborative programs with government science agencies including National Science Foundation and Department of Energy research centers.
As a publicly traded company, Schrödinger reports revenues from software licenses, services, and discovery collaborations. Its capital allocation and governance structure reflect practices seen at life science software firms and biotech companies such as Illumina and Biogen. Executive leadership includes scientists and managers with prior affiliations to Merck & Co., AbbVie, and academic institutions. The company’s board features directors with backgrounds at investment firms and research institutions including Goldman Sachs-affiliated investors and faculty from Harvard Medical School and Columbia University. Financial disclosures highlight R&D investments and partnerships comparable to peer companies like Zymergen and Exscientia.
Schrödinger has navigated typical industry disputes over intellectual property, licensing, and contractual milestones similar to litigation previously seen involving Gilead Sciences and Roche. Patent portfolios and software licensing agreements have been the subject of negotiation with collaborators and competitors, echoing disputes in the biotechnology sector involving organizations such as Genentech and Amgen. Regulatory interactions related to drug candidates advanced through collaborations have involved standard review pathways at U.S. Food and Drug Administration and ethical considerations paralleling debates in translational research at National Institutes of Health.